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ABSTRACT
Objective: Genetic disorders enter the differential diagnosis of common neurologic diseases, but
their overall prevalence is not known. We set out to determine their minimum prevalence.
Methods: Meta-analysis of epidemiologic data gathered from the same geographic region in the
North of England.
Results: Monogenic neurologic disorders affect at least 90.9/100,000 (95% confidence interval
87.6–94.3), or 1 in 1,100 of the population in Northern England.
Conclusion: As a group, neurogenetic disorders are not rare. These findings have implications for
clinical service delivery. Neurology® 2015;85:1195–1201
GLOSSARY
ADCA5 autosomal dominant cerebellar ataxia;ALS5 amyotrophic lateral sclerosis;ARCA5 autosomal recessive cerebellar
ataxia; CI 5 confidence interval; CMT 5 Charcot-Marie-Tooth; DOA 5 dominant optic atrophy; HD 5 Huntington disease;
HNPP 5 hereditary neuropathy with liability to pressure palsy; HSP 5 hereditary spastic paraparesis; LHON 5 Leber hered-
itary optic neuropathy; mtDNA 5 mitochondrial DNA.
Recent advances in molecular diagnostics have expanded our understanding of the heritable basis of
neurologic disease. The possibility of a highly penetrant mutation in a single gene enters the differ-
ential diagnosis of the most common neurologic disorders. If the inherited disorder presents late in
life, or has a reduced penetrance, then there may be no affected relatives, so the absence of a family
history does not preclude a genetic diagnosis. The widespread availability of inexpensive DNA tests
has made it easier than ever to reach a molecular diagnosis in a patient with a suspected neurogenetic
disorder, but the overall prevalence of these diseases has not been established. Herein, we present the
results of a systematic review of neurogenetic disorders in the North of England, where the stable
population has provided an ideal substrate for genetic epidemiology.1
METHODS We reviewed the reported prevalence of neurogenetic disorders, here defined as neurologic conditions known to be
caused by highly penetrant mutations in a single gene (so-called “monogenic” or “single gene” disorders). We did not include data
on common neurologic conditions, such as Alzheimer disease, Parkinson disease, motor neuron disease (amyotrophic lateral sclerosis
[ALS]), or inherited dystonias, in which only a minority of cases are caused by a single highly penetrant gene defect, although their likely
contribution is discussed later in the article.
A systematic literature review was undertaken by searching PubMed (MEDLINE) listings from January 1966 to April 2015 for relevant
articles using the following terms: “ataxia,” “neuropathy,” “muscle disease,” “myopathy,” “dystrophy,” “Huntington,” “mitochondrial,” “optic
atrophy,” or “hereditary spastic paraparesis” combined with the terms “epidemiology,” “prevalence,” or “incidence.” There was no language
restriction. The final reference list was generated on the basis of relevance to the topics covered in this review. Priority was given to studies based on
amolecular genetic diagnosis rather than those based on clinical or biochemical criteria alone. Articles containing disease prevalence statistics for the
North of England (see the figure for region definition) were included. The minimum point prevalence for each disorder was calculated using live
affected cases and UK Office for National Statistics’ population estimates for the North of England (appendix e-1 on theNeurology®Web site at
Neurology.org) for the precise census date in each study.2 Exact 95% confidence intervals (CIs) were calculated by the Clopper-Pearson method.
RESULTS The systematic review identified the most up-to-date published prevalence data for the majority of
neurogenetic disorders from the North of England between 1966 and 2015 (table). For hereditary spastic
paraparesis (HSP), there were no published data from the United Kingdom and so we calculated a prevalence
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estimate from the Northern England neurogenetic
database, an up-to-date census of patients with
genetic conditions maintained by the Northern
Genetics Service, which is based in Newcastle upon
Tyne and serves the geographic region shown in the
figure. Overall, the minimum point prevalence for
neurogenetic disorders in the North of England was
90.9/100,000 (95% CI 87.6–94.3). The specific
studies contributing to this result are described below.
Inherited muscle disease. The point prevalence of all
causes of genetic muscle disease was determined by
Norwood et al.3 by a survey of a specialist muscle
disease clinic in the North of England. From a clinic
population of 1,100 patients registered with the New-
castle neuromuscular team, the combined point prev-
alence for all genetic muscle disease of 37.0/100,000
(95% CI 34.8–39.2) was established. The 5 main
conditions represented in the population were
myotonic dystrophy with a point prevalence of
10.6/100,000 (95% CI 9.6–11.6), dystrophinopa-
thies at 8.5/100,000 (95% CI 7.6–9.4), facioscapu-
lohumeral muscular dystrophy of 3.9/100,000 (95%
CI 3.3–4.7), limb-girdle muscular dystrophy 2.3/
100,000 (95% CI 1.8–2.9), and spinal muscular
atrophy 1.9/100,000 (95% CI 1.4–2.4). Twelve
further muscle disorders made up the remaining
diagnoses including congenital muscular dystrophy
with a point prevalence of 0.90/100,000 (95% CI
0.60–1.3) and 4 patients had X-linked Emery-
Dreifuss muscular dystrophy giving a point
prevalence of 0.13 (95% CI 0.04–0.34).3
The prevalence of GNE (glucosamine [UDP-N-
acetyl]-2-epimerase/N-acetylmannosamine kinase)
myopathy, a rare distal myopathy with inclusion bod-
ies estimated under the category of “distal myopa-
thies,”3 was recently assessed separately in a
Northern England cohort.4 Cases were identified
from referral records to the Newcastle MRC
Figure North East England
Map of the world showing the United Kingdom (A) and the North of England (shaded in A). (B) North of England region and
Newcastle upon Tyne and the population regions specified in appendix e-1.
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Neuromuscular GNE diagnostic service, also based in
the Northern Genetic Service. Genetics testing became
available in 2010, after which the center received 87
referrals—64% from England, 13% Scotland, 14%
fromNorthern Ireland, and the remaining referrals from
abroad. Twenty-six cases of GNE myopathy were iden-
tified, 7 of these from England (3 from Northern Eng-
land, 4 from Southern England), 10 from Scotland, 8
from Northern Ireland, and 1 from the Republic of
Ireland. Using these population estimates, a point prev-
alence of GNE myopathy in Northern England can be
calculated as 1/million (95% CI 0.0–2.9) and for the
UK as 0.4/million (95% CI 0.0–0.6).
Inherited neuropathies. The most recent UK epidemi-
ologic study of inherited neuropathies was published
Table Minimum prevalence of neurogenetic disorders in the North of England
Years of study Cases (population) Source of patients Disorder
Prevalence, per 100,000
(95% CI)
Muscle disease 37.0 (34.8–39.2)
Norwood et al.3 2007 1,100 (2,990,000) Neuromuscular disease clinic Myotonic dystrophy 10.6 (9.6–11.6)
Dystrophinopathies 8.5 (7.6–9.4)
FSHD 3.9 (3.3–4.7)
LGMD 2.3 (1.8–2.9)
SMA 1.9 (1.4–2.4)
CMD 0.90 (0.60–1.3)
EDMD-X 0.13 (0.04–0.34)
Inherited neuropathies 11.8 (10.6–13.1)
Foley et al.5 2010 352 (2,990,000) Clinical neurogenetic, clinical
neurophysiology, and molecular
diagnostic services
CMT disease 9.8 (8.7–11.0)
HNPP 2.0 (1.5–2.5)
Inherited ataxia 5.8 (4.9–6.9)
Craig et al.6 2001 26 (2,516,500) Regional neurogenetics clinic SCA6 1.3 (1.0–1.8)
ADCA (estimated) 5.2 (4.3–6.1)
Craig et al.7 2005 3 (2,516,500) Regional neurogenetics clinic SCA17 0.12 (0.00–0.35)
Pfeffer et al.8 2011–2012 17 (2,134,449) Regional neurogenetics clinic SPG7 0.80 (0.00–1.28)
Movement disorders 18.3 (8.3–34.6)
Evans et al.9 1990–2010 9 (49,317) Electronic medical records from
national primary care database
Huntington disease 18.3 (8.3–34.6)
Mitochondrial 7.6 (6.5–8.9)
Gorman et al.12 1990–2011 163 (2,134,449) Mitochondrial disease clinic and
genetic diagnostic service
mito disease (non-
LHON)
7.6 (6.5–8.9)
mito mutations (non-
LHON)
7.8 (6.8–9.0)
Inherited optic neuropathies 7.8 (6.8–8.8)
Gorman et al.12 1990–2011 78 (2,134,449) Mitochondrial disease clinic and
genetic diagnostic service
LHON disease 3.7 (2.9–4.6)
LHON mutations 4.4 (3.7–5.3)
Yu-Wai-Man and
Chinnery14
1990–2013 126 (3,061,400) Mitochondrial genetic diagnostic
service
DOA 4.1 (3.4–4.9)
Hereditary spastic
paraparesis
2.8 (2.2–3.6)
Unpublished 2014 74 (2,610,000) Regional neurogenetics clinic Sporadic, AD, AR 2.8 (2.2–3.6)
Total 90.9 (87.6–94.3)
Abbreviations: AD 5 autosomal dominant; ADCA 5 autosomal dominant cerebellar ataxia; AR 5 autosomal recessive; CI 5 confidence interval; CMD 5
congenital muscular dystrophy; CMT 5 Charcot-Marie-Tooth; DOA 5 dominant optic atrophy; EDMD 5 Emery-Dreifuss Muscular Dystrophy; FSHD 5
facioscapulohumeral dystrophy; HNPP 5 hereditary neuropathy with liability to pressure palsy; LGMD 5 limb-girdle muscular dystrophy; LHON 5 Leber
hereditary optic neuropathy; mito 5 mitochondrial; SCA 5 spinocerebellar ataxia; SMA 5 spinal muscular atrophy.
All studies contain North of England (UK) data. The total prevalence estimate (with 95% CI) was derived using the median North of England population
estimate from the time period of all included studies.
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in 2012.5 The authors calculated the point prevalence
of Charcot-Marie-Tooth (CMT) disease and
hereditary neuropathy with liability to pressure
palsy (HNPP) in a Northern England cohort using
3 databases, identifying cases using clinical, molecular
diagnostic, and electrophysiologic criteria. From
these, 352 individuals from 275 families were
identified with a clinical diagnosis of CMT disease
or HNPP. A minimum prevalence of CMT disease in
the Northern region was estimated at 9.8/100,000
(95% CI 8.7–11.0) and for HNPP at 2.0/100,000
(95% CI 1.5–2.5), giving a combined minimum
prevalence of 11.8/100,000 (95% CI 10.6–13.1).
Inherited ataxias. Two studies in the North of England
region calculated point prevalence of SCA6 and
SCA17mutations, which both cause autosomal dom-
inant cerebellar ataxia (ADCA). The first of these
evaluated the prevalence of SCA6 mutations,6 which
lead to an adult-onset progressive syndrome of ataxia,
dysarthria, and nystagmus. Twenty-six cases
heterozygous for the CAG repeats were identified
from 16 genealogically distinct families. Using their
data, a minimum prevalence of ADCA due to SCA6
can be estimated as 1.3/100,000 (95% CI 1.0–1.8)
and in adults aged 45 years or older as 3.2/100,000
(95% CI 2.1–4.3). Because SCA6 mutations account
for approximately 20% of ADCA in the region,
the minimum prevalence of ADCA in the general
population can be calculated as 5.2/100,000 (95%
CI 4.3–6.1). The same group conducted a further
study assessing the prevalence of SCA17,7 a
dominantly inherited ataxia with extrapyramidal
features and dementia presenting with a
Huntington disease (HD)-like phenotype. Ninety
families with suspected HD and 192 families with
undiagnosed ataxia were included and screened for
SCA17 mutations. Two of the 192 patients with
undiagnosed ataxia, but none of the HD-like
patients, were found to have (CAG/CAA)n
expansions larger than the control range. Using
these data, a minimum prevalence of SCA17 was
estimated as 0.12/100,000 (95% CI 0.00–0.35).
There were no UK studies specifically studying the
prevalence of autosomal recessive ataxia, apart from
one focused on SPG7 in North East England,8 which
reported a prevalence of 0.80/100,000 (95% CI
0.00–0.13).
Movement disorders. The prevalence of HD in a UK
cohort was estimated using the UK’s General Practice
research database, the world’s largest computerized
database of primary care medical records.9 Patients
older than 21 years with a diagnosis of HD were
included (n 5 1136), and prevalence rates were cal-
culated annually between 1990 and 2010. The prev-
alence of HD increased considerably between with
this period, with a prevalence of 5.4/100,000 (95%
CI 3.8–7.5) in 1990 up to a prevalence of 12.3/
100,000 (95% CI 11.2–13.5) in 2010. These
increased rates over time were predominantly repre-
sented in patients older than 60 years, whereby a
prevalence in the 60 to 69 age group of 12.6/
100,000 (95% CI 9.1–17.1) in 1990 rose to 24.2/
100,000 (95% CI 21.1–27.5) in 2010 and in the
701 group a prevalence of 7.2/100,000 (95% CI
4.8–10.4) in 1990 rose to 15.6/100,000 (95% CI
13.2–18.3) in 2010. Results were further analyzed
on a regional basis showing that the North East of
England and Scotland had the highest prevalence
rates (18.3/100,000: 95% CI 8.4–34.6 and 16.1/
100,000: 95% CI 10.8–22.9, respectively) while
the lowest rates were found in London (5.4/
100,000: 95% CI 3.0–8.8).
Mitochondrial disease. The prevalence of mitochon-
drial disease was initially estimated in 2000,10 and
subsequently revised,11,12 based on referrals to a
national diagnostic service for rare mitochondrial dis-
eases in Newcastle upon Tyne in the North of
England. The minimum prevalence of mitochondrial
disease was established through molecular genetics
testing for mitochondrial DNA (mtDNA) point mu-
tations and deletions, and nuclear-genetic causes of
mitochondrial disease in adults (defined as older than
16 years; SPG7 and OPA1 are included in the ataxia
and inherited optic neuropathy sections of this report,
respectively).12 Both adults and children were
included to establish those at risk of mitochondrial
disease. By excluding mtDNA mutations that cause
Leber hereditary optic neuropathy (LHON,
considered separately in the section “Inherited optic
neuropathies” below), the minimum prevalence of
non-LHON mitochondrial disease mutations in the
population was calculated as 7.8/100,000 (95% CI
6.8–9.0) and the minimum prevalence of non-
LHON mitochondrial disease as 7.6/100,000 (95%
CI 6.5–8.9).
Inherited optic neuropathies. The 2 principal inherited
optic neuropathies are LHON and autosomal domi-
nant optic atrophy (DOA).
The prevalence of LHONwas established through
the prospective mtDNA genetic testing of patients
with unexplained visual failure or suspected LHON
in the Northern Genetic Service over a 21-year period
(January 1990 to May 2011).12 Within this popula-
tion, the prevalence of LHON was calculated as 3.7/
100,000 (95% CI 2.9–4.6), while the prevalence of
mtDNA LHON mutations, representing those “at
risk” within the population, was 4.4/100,000 (95%
CI 3.7–5.3).
The same center previously established the preva-
lence of DOA using North of England neurogenetic
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and ophthalmology clinical databases.13 Seventy-six
patients from 22 families were identified with a clin-
ical diagnosis of DOA, and OPA1 gene sequencing
was performed on this group. Those found to be
negative for this were further screened for OPA1
rearrangements and OPA3 mutations. The majority
(14/22, 63.6%) of families with DOA carried OPA1
mutations while OPA1 rearrangements were only
found in one family and no OPA3 mutations were
detected in the study cohort. The calculated point
prevalence estimate from this data for clinically
determined DOA was 2.9/100,000 (95% CI 2.3–
3.5) with the point prevalence of molecularly con-
firmed OPA1-positive DOA as 2.1/100,000 (95%
CI 1.6–2.7). A recent update from the same group
included a further 8 OPA1-positive and 5 OPA1-
negative families resulting in a revised point preva-
lence estimate for DOA of 4.1/100,000 (95% CI
3.7–4.5).14
Hereditary spastic paraparesis. We found no published
UK epidemiologic data on the prevalence of HSP.
We identified cases in the North of England using
the Northern Genetics Service database to identify
patients with suspected and genetically confirmed
HSP. All patients had brain and spinal cord imaging
to exclude a structural or inflammatory cause for the
spastic paraparesis, and all had normal CSF examina-
tion. From a population of 2.61 million (mid-2013
estimate) in the North East region, 176 individual
cases from 55 genealogically distinct families with
clinical HSP were identified. Of this group, 74 cases
(44.3%) had a confirmed genetic diagnosis giving
a minimum point prevalence of confirmed HSP of
2.8/100,000 (95% CI 2.2–3.6). This did not include
patients with SPG7 who were identified through their
ataxic presentation and were included in the ataxia
section above.
DISCUSSION Here we show that approximately 1 in
1,100 of the general population is directly affected by
a “single gene” neurologic disorder. This figure is
likely to be an underestimate for several reasons. First,
most of the studies we included had ascertained cases
through hospital referrals, and not by systematically
investigating a community-based cohort. This
approach introduces a bias toward younger, more
highly motivated individuals who seek specialist
advice about a rare diagnosis. Older patients may be
less inclined to pursue a precise diagnosis in a
specialist center, given that there may be little hope
of a cure. Many of the disorders described here have
an age-related penetrance, so the underascertainment
of older individuals is likely. Prospective community-
based studies usually yield higher prevalence figures,
but are particularly challenging for rare diseases
because of the very large sample size required to
reliably estimate the prevalence.15 Second, some of
the studies did not incorporate comprehensive
genetic testing, raising the possibility that some of
the cases were misdiagnosed as a noninherited
disorder because there was no family history, and
missed altogether. Family history is not a reliable
guide to monogenic disease because a positive
family history depends on the degree of relative
affected,16 and even high penetrance mutations
frequently present without a family history.17
Finally, it is also important to note that here we
describe the results of several different studies
performed at different time points. Most, but not
all, of the studies were performed in the same
geographic region but had subtly different forms of
case ascertainment and encompassed different age
groups (table).
Could our results be an overestimate? This is
unlikely because most of the studies we included were
performed in the North of England, which has a well-
defined outbred stable population of largely white
European extraction.1 Given the limited consanguin-
ity, it is unlikely that the prevalence estimates of
recessive neurogenetic disorders are unusually high.
When taken together, our findings are therefore likely
to have broader relevance for other similar popula-
tions. When compared with prevalence data from
studies worldwide, most of our estimates fit comfort-
ably within previously delineated ranges: an earlier
estimate of the prevalence of inherited muscle disease
was 1 in 3,000 or 33.3/100,000,18 and a recent review
has estimated the worldwide prevalence of HSP and
ADCA as 0.1–9.6/100,000 and 0.7–5.6/100,000,
respectively.19 Prevalence estimates for sporadic idio-
pathic cerebellar ataxia and autosomal recessive cere-
bellar ataxia (ARCA) were not obtainable for our
region but can be estimated from a study in South
Wales, UK, a region with a stable population and
similar demographic.20 From a group of 76 cases with
late-onset cerebellar ataxia identified from general
practice, hospital and health authority databases, as
well as through personal notification from consultant
neurologists, 4 were classified as ARCA, giving a prev-
alence estimate of 0.53/100,000 (95% CI 0–1.38).
We note, when comparing these data with the world-
wide review,19 the prevalence estimate for ARCAs
represents the lower end of a worldwide range span-
ning from 0.1 to 7.2/100,000. As noted by the au-
thors of theWelsh study,20 this is likely attributable to
methodologic limitations in case ascertainment as
well as the challenge of classifying patients with an
undetermined family history. It was further restricted
in considering only “late-onset” cerebellar ataxia
(symptom onset at age 18 years or older), which is
likely to significantly underestimate the overall
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prevalence of ARCA. In a similar way, estimates of
the prevalence of mitochondrial disorders10,12 did not
include affected pediatric cases. In the age group
younger than 16 years, the minimum prevalence of
mitochondrial disorders has been estimate at 5.0/
100,000 (95% CI 4.0–6.2),21 indicating that, for
these conditions, our quoted figures provide an
underestimate. Likewise, with the almost exponential
increase in disease gene discovery, the number of “sin-
gle gene” neurogenetic disorders is on the increase,22
further emphasizing that the figures we report here
are likely to be a conservative underestimate.
We deliberately did not include genetic forms of
common neurodegenerative diseases in our review
because of the difficulty in diagnosing inherited forms
of the disorder, which may be clinically indistinguish-
able from sporadic cases. However, using UK preva-
lence data for the principal neurodegenerative
disorders Alzheimer disease (UK prevalence 1,100/
100,000, of which ;110/100,000 [;1%] are mon-
ogenic23), Parkinson disease (UK prevalence 300/
100,000, of which ;30/100,000 [;10%] are mon-
ogenic24,25), motor neuron disease (ALS, UK preva-
lence 6/100,000, of which;0.3/100,000 [;5%] are
monogenic26), and DYT1 dystonia (prevalence ;5/
100,00027), the combined overall minimum preva-
lence of neurogenetic disorders increases to ;234/
100,000, or at least 1 in 423 of the UK population.
This figure does not include sporadic neurodegener-
ative diseases with a complex genetic architecture
involving many different genetic loci, such as APOE,
which has a moderately strong influence on the risk of
developing Alzheimer disease. It also cannot include
genetic forms of neurodegenerative disease due to
hitherto unknown genes. This is important to recog-
nize, given the recent unexpected finding that hexa-
nucleotide repeat expansions in C9ORF72 cause a
substantial proportion of cases of ALS and other neu-
rodegenerative diseases.28,29 For these reasons, even
the prevalence of 1 in 423 is likely to be an
underestimate.
These findings have major implications. For
example, the average UK primary care practice will
have at least 16 patients with single gene neurogenetic
disorders on their records30 and with an aging popu-
lation, these figures are likely to increase. Moreover, a
UK neurologist will have on average 80 patients with
a neurogenetic disorder within their referral area.31
The majority of the disorders discussed here have
no treatment and cause progressive disability, often
over several decades. The effect on families and med-
ical and social services will be substantial. Second, our
estimates do not account for the impact of the genetic
diagnoses on at-risk family members, who may
request genetic counseling and prenatal and preim-
plantation diagnosis to prevent recurrence. Finally,
with the mainstream introduction of exome and
whole genome sequencing in clinical practice, the
number of unexpected predictive tests will also
increase, placing even greater strain on clinical service
provision, and emphasizing the need to develop treat-
ments that can slow down or prevent these disorders.
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Save These Dates for AAN CME Opportunities!
Mark these dates on your calendar for exciting continuing education conferences by the American
Academy of Neurology. Learn more at AAN.com/conferences.
AAN Fall Conference
• October 16–18, 2015, Las Vegas, NV, The Cosmopolitan of Las Vegas
2016 Breakthroughs in Neurology Conference
• January 15–18, 2016, Orlando, FL, Omni Orlando Resort at ChampionsGate
AAN Annual Meeting
• April 15–21, 2016, Vancouver, BC, Canada, Vancouver Convention Centre
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